Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting
Arvinas (NASDAQ: ARVN) announced it will present new preclinical combination data for ARV-393, their investigational PROTAC BCL6 degrader, at the upcoming AACR Annual Meeting in Chicago (April 25-30, 2025). The presentation will focus on ARV-393's potential combination with standard lymphoma treatments.
The research highlights ARV-393, a PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein (BCL6), which is a transcriptional repressor and major driver of B-cell lymphomas. The poster presentation, titled 'ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma Models,' will be presented on April 28, 2025.
Arvinas (NASDAQ: ARVN) ha annunciato che presenterà nuovi dati preclinici sulla combinazione di ARV-393, il loro degrader PROTAC sperimentale per BCL6, durante il prossimo AACR Annual Meeting a Chicago (25-30 aprile 2025). La presentazione si concentrerà sul potenziale di ARV-393 in combinazione con i trattamenti standard per il linfoma.
La ricerca evidenzia ARV-393, un degrader PROteolysis TArgeting Chimera (PROTAC) che prende di mira la proteina B-cell lymphoma 6 (BCL6), un repressore trascrizionale e principale fattore responsabile dei linfomi a cellule B. Il poster, intitolato "ARV-393, un degrader PROteolysis TArgeting Chimera (PROTAC) per BCL6, combinato con biologici o inibitori a piccola molecola induce regressioni tumorali in modelli di linfoma diffuso a grandi cellule B," sarà presentato il 28 aprile 2025.
Arvinas (NASDAQ: ARVN) anunció que presentará nuevos datos preclínicos de combinación para ARV-393, su degradador PROTAC BCL6 en investigación, en la próxima reunión anual de AACR en Chicago (25-30 de abril de 2025). La presentación se centrará en el potencial de ARV-393 en combinación con tratamientos estándar para el linfoma.
La investigación destaca a ARV-393, un degradador PROteolysis TArgeting Chimera (PROTAC) dirigido a la proteína B-cell lymphoma 6 (BCL6), un represor transcripcional y principal impulsor de los linfomas de células B. La presentación en póster, titulada "ARV-393, un degradador PROteolysis TArgeting Chimera (PROTAC) para BCL6, combinado con biológicos o inhibidores de molécula pequeña induce regresiones tumorales en modelos de linfoma difuso de células B grandes," se presentará el 28 de abril de 2025.
Arvinas (NASDAQ: ARVN)는 다가오는 2025년 4월 25일부터 30일까지 시카고에서 열리는 AACR 연례회의에서 연구 중인 PROTAC BCL6 분해제 ARV-393의 새로운 전임상 병용 데이터 발표를 예고했습니다. 발표는 ARV-393가 표준 림프종 치료제와 병용될 가능성에 초점을 맞출 예정입니다.
연구는 전사 억제제이자 B세포 림프종의 주요 원인인 B세포 림프종 6 단백질(BCL6)을 표적으로 하는 PROteolysis TArgeting Chimera(PROTAC) 분해제인 ARV-393를 강조합니다. 'ARV-393, PROteolysis TArgeting Chimera(PROTAC) BCL6 분해제, 생물학제 또는 소분자 억제제와 병용 시 확산성 대형 B세포 림프종 모델에서 종양 퇴축 유도'라는 제목의 포스터 발표는 2025년 4월 28일에 진행됩니다.
Arvinas (NASDAQ : ARVN) a annoncé qu'elle présentera de nouvelles données précliniques en combinaison pour ARV-393, son dégradeur PROTAC BCL6 en investigation, lors de la prochaine réunion annuelle de l'AACR à Chicago (du 25 au 30 avril 2025). La présentation portera sur le potentiel d'ARV-393 en combinaison avec les traitements standards du lymphome.
La recherche met en lumière ARV-393, un dégradeur PROteolysis TArgeting Chimera (PROTAC) ciblant la protéine B-cell lymphoma 6 (BCL6), un répresseur transcriptionnel et un moteur principal des lymphomes à cellules B. La présentation sous forme d'affiche, intitulée « ARV-393, un dégradeur PROteolysis TArgeting Chimera (PROTAC) BCL6, combiné avec des biologiques ou des inhibiteurs de petites molécules induit des régressions tumorales dans des modèles de lymphome diffus à grandes cellules B », sera présentée le 28 avril 2025.
Arvinas (NASDAQ: ARVN) gab bekannt, dass es neue präklinische Kombinationsdaten für ARV-393, ihren experimentellen PROTAC BCL6-Degrader, auf der bevorstehenden AACR Jahrestagung in Chicago (25.-30. April 2025) vorstellen wird. Die Präsentation wird sich auf das Potenzial von ARV-393 in Kombination mit Standardbehandlungen für Lymphome konzentrieren.
Die Forschung hebt ARV-393 hervor, einen PROteolysis TArgeting Chimera (PROTAC) Degrader, der das B-Zell-Lymphom-6-Protein (BCL6) anvisiert, einen Transkriptionsrepressor und Haupttreiber von B-Zell-Lymphomen. Die Posterpräsentation mit dem Titel „ARV-393, ein PROteolysis TArgeting Chimera (PROTAC) BCL6-Degrader, kombiniert mit Biologika oder kleinmolekularen Inhibitoren, induziert Tumorrückgänge in Modellen des diffus großzelligen B-Zell-Lymphoms“ wird am 28. April 2025 vorgestellt.
- Preclinical data shows tumor regression in lymphoma models
- Successful combination potential with existing standard of care treatments
- Still in early preclinical stage, far from market approval
- No human trial data available yet
Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of care therapies
NEW HAVEN, Conn., April 21, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that new preclinical combination data for ARV-393 will be presented at the American Association for Cancer Research® (AACR) Annual meeting, April 25-30, 2025 in Chicago, Illinois. The poster highlights the potential for ARV-393 to be combined with various standard of care lymphoma treatments.
ARV-393 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas.
Presentation details are as follows:
Poster Title: ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma Models
Abstract: 1655
Session Title: Degraders and Glues 2
Session Type: Experimental and Molecular Therapeutic
Location: Poster Section 18
Poster Board Number: 15
Date: Monday, April 28, 2025
Lecture Time: 9:00 a.m. – 12:00 p.m. CT
The full abstract can be accessed via the AACR 2025 online interactive program.
About ARV-393
ARV-393 is an investigational PROteolysis TArgeting Chimera (PROTAC) designed to degrade B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas. The BCL6 protein facilitates B cell tolerance of rapid proliferation and somatic gene recombination via repressing cell cycle checkpoints, terminal differentiation, apoptosis, and the DNA damage response. PROTAC-mediated degradation has the potential to address the traditional undruggable nature of BCL6. ARV-393 is currently in a Phase 1 clinical trial in patients with relapsed/refractory non-Hodgkin lymphoma.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROteolysis TArgeting Chimera (PROTAC) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the potential for Arvinas’ investigational oral PROteolysis TArgeting Chimera (PROTAC) degrader ARV-393 to treat relapsed/refractory non-Hodgkin lymphoma; the potential for ARV-393 to be combined with various standard of care lymphoma treatments; and PROTAC-mediated degradation having the potential to address the traditional undruggable nature of B-cell lymphoma 6. All statements, other than statements of historical facts, contained in this press release, including statements regarding Arvinas’ strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas will be able to successfully conduct and complete development for its product candidates, including ARV-393, including whether Arvinas initiates and completes clinical trials for its product candidates and receives results from its clinical trials on its expected timelines or at all; Arvinas’ ability to protect its intellectual property portfolio; whether Arvinas’ cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
jeff.boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
kirsten.owens@arvinas.com
FAQ
What are the key findings of Arvinas' ARV-393 preclinical study for lymphoma treatment?
How does Arvinas' ARV-393 PROTAC degrader work in treating lymphoma?
When will Arvinas present the ARV-393 preclinical data at AACR 2025?
What type of cancer is Arvinas' ARV-393 being developed to treat?
